Dose escalation to 84 Gy with concurrent chemotherapy in stage III NSCLC appears excessively toxic: Results from a prematurely terminated randomized phase II trial-Reference-Cited by-同舟云学术

Dose escalation to 84 Gy with concurrent chemotherapy in stage III NSCLC appears excessively toxic: Results from a prematurely terminated randomized phase II trial

Published:2018-08 Issue: Volume:122 Page:180-186
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Hallqvist Andreas,Bergström Stefan,Björkestrand Hedvig,Svärd Anna-Maja,Ekman Simon,Lundin Erik^ORCID,Holmberg Erik,Johansson Mikael,Friesland Signe,Nyman Jan

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference30 articles.

1. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial;Rosenman;Int. J. Radiat. Oncol. Biol. Phys.,2002

2. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial;Socinski;J. Clin. Oncol.,2004

3. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma;Bradley;Int. J. Radiat. Oncol. Biol. Phys.,2005

4. Final results of a phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy;Belderbos;Int. J. Radiat. Oncol. Biol. Phys.,2006

5. Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer;van Baardwijk;J. Clin. Oncol.,2010

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In Response to Arcidiacono et al.: “Should dose intensification be discontinued or should accelerated schemes remain an important area of clinical research?”;Radiotherapy and Oncology;2023-08

2. Personalized mid-course FDG-PET based adaptive treatment planning for non-small cell lung cancer using machine learning and optimization;Physics in Medicine & Biology;2022-09-13

3. Optimizing Lung Cancer Radiotherapy Treatments Using Personalized Dose-Response Curves;Medical Radiology;2022

4. X-ray-responsive polypeptide nanogel for concurrent chemoradiotherapy;Journal of Controlled Release;2021-04

5. Dose and fractionation schedules in radiotherapy for non-small cell lung cancer;Translational Lung Cancer Research;2021-04